206 related articles for article (PubMed ID: 20570743)
21. Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs.
Ward G; Milliken P; Patel B; McMahon N
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):106-13. PubMed ID: 22525003
[TBL] [Abstract][Full Text] [Related]
22. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog.
Taylor GL; Patel B; Sullivan AT
J Pharmacol Toxicol Methods; 2007; 56(2):212-7. PubMed ID: 17582788
[TBL] [Abstract][Full Text] [Related]
24. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation.
Adeyemi O; Roberts S; Harris J; West H; Shome S; Dewhurst M
J Pharmacol Toxicol Methods; 2009; 60(2):159-66. PubMed ID: 19616109
[TBL] [Abstract][Full Text] [Related]
25. Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants.
Chui RW; Fosdick A; Conner R; Jiang J; Bruenner BA; Vargas HM
J Pharmacol Toxicol Methods; 2009; 60(1):58-68. PubMed ID: 19426820
[TBL] [Abstract][Full Text] [Related]
26. Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques.
Skinner M; Xing G; Lu J; Ren J; Oldman K
J Pharmacol Toxicol Methods; 2017; 85():38-48. PubMed ID: 28065822
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the sensitivity of a new fully implantable telemetry device and the importance of simultaneously measuring cardiac output and left ventricular pressure.
McKee J; Daller J; Baumgartner B; Pettinger S
J Pharmacol Toxicol Methods; 2014; 69(3):229-36. PubMed ID: 24468466
[TBL] [Abstract][Full Text] [Related]
28. An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey.
Moscardo E; McPhie G; Fasdelli N; Giarola A; Tontodonati M; Dorigatti R; Meecham K
J Pharmacol Toxicol Methods; 2010; 62(2):95-106. PubMed ID: 20601019
[TBL] [Abstract][Full Text] [Related]
29. A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 2: Pharmacological validation.
Authier S; Tanguay JF; Gauvin D; Fruscia RD; Troncy E
J Pharmacol Toxicol Methods; 2007; 56(2):122-30. PubMed ID: 17587605
[TBL] [Abstract][Full Text] [Related]
30. Effects of moxifloxacin on QT interval in conscious dogs.
Mittelstadt SW; Hart SM
J Vet Pharmacol Ther; 2005 Jun; 28(3):253-6. PubMed ID: 15953198
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.
Prior H; McMahon N; Schofield J; Valentin JP
J Pharmacol Toxicol Methods; 2009; 60(2):167-73. PubMed ID: 19539041
[TBL] [Abstract][Full Text] [Related]
32. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced effects on cardiovascular function in pentobarbital anesthetized guinea-pigs: invasive LVP measurements versus the QA interval.
Johnson DM; Geys R; Lissens J; Guns PJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):152-9. PubMed ID: 22813982
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
[TBL] [Abstract][Full Text] [Related]
35. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
[TBL] [Abstract][Full Text] [Related]
36. Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs.
Chiang AY; Smith WC; Main BW; Sarazan RD
J Pharmacol Toxicol Methods; 2004; 50(2):121-30. PubMed ID: 15385086
[TBL] [Abstract][Full Text] [Related]
37. The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs.
Chiang AY; Guth BD; Pugsley MK; Foley CM; Doyle JM; Engwall MJ; Koerner JE; Parish ST; Dustan Sarazan R
J Pharmacol Toxicol Methods; 2018; 92():43-51. PubMed ID: 29505899
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism.
Norton K; Iacono G; Vezina M
J Pharmacol Toxicol Methods; 2009; 60(2):193-7. PubMed ID: 19523528
[TBL] [Abstract][Full Text] [Related]
39. A cardiovascular monitoring system in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 1: Non-pharmacological validation.
Authier S; Tanguay JF; Gauvin D; Di Fruscia R; Fournier S; Chaurand F; Troncy E
J Pharmacol Toxicol Methods; 2007; 56(2):115-21. PubMed ID: 17587601
[TBL] [Abstract][Full Text] [Related]
40. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog.
Ollerstam A; Persson AH; Visser SA; Fredriksson JM; Forsberg T; Nilsson LB; Eklund G; Wiklund SJ; Gabrielsson J; Duker G; Al-Saffar A
J Pharmacol Toxicol Methods; 2007; 55(1):35-48. PubMed ID: 16581270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
